Broader Formulary Coverage Linked to Lower Odds of MS Relapse
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 8, 2025 -- Broader formulary coverage is associated with lower odds of multiple sclerosis (MS) relapse among Medicare beneficiaries, according to a study published online Aug. 1 in JAMA Network Open.
Barbara Blaylock, Ph.D., from Blaylock Health Economics LLC in Reno, Nevada, and colleagues examined the association between the breadth of formulary coverage for MS disease-modifying therapies and MS relapse in a retrospective cohort study that analyzed 100 percent Medicare administrative data from 2018 to 2022. Beneficiaries with stand-alone prescription drug plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs) were followed for at least five quarters (baseline: quarters 1 to 4; follow-up: quarter 5).
A total of 50,162 unique beneficiaries in PDPs and 34,708 in MA-PDs were included in the claims analysis. The researchers found that the MS relapse rate was greater for low- versus high-coverage PDPs and MA-PDs (odds ratios, 0.88 and 0.88). There was an association for broader formulary coverage during baseline with less MS relapse during follow-up in multivariable analyses (adjusted odds ratios, 0.93 and 0.94 for drugs and classes for PDP; 0.88 and 0.92 for drugs and classes for MA-PD, respectively).
"Patients with MS may need to try multiple drugs to find what works best for them. Broad formulary exclusions ultimately undermine the individualized care these patients need," lead author Geoffrey Joyce, Ph.D., from the University of Southern California, Los Angeles, said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
Mortality Up for Children With Leukemia From Lowest SES Neighborhoods
THURSDAY, Aug. 28, 2025 -- Children with acute lymphoblastic leukemia (ALL) from the lowest socioeconomic status (SES) neighborhoods have an increased risk for mortality...
AI-Enabled Bundle of Sensors, Coaching Aids Type 2 Diabetes Outcomes
THURSDAY, Aug. 28, 2025 -- An artificial intelligence (AI)-enabled bundled system of sensors and coaching facilitates significant improvements in glycemic outcomes and...
Shared, Sex-Specific Body Fat Patterns Linked to Cardiovascular Aging
WEDNESDAY, Aug. 27, 2025 -- Shared and sex-specific patterns of body fat are associated with changes in cardiovascular aging, according to a study published online Aug. 22 in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.